favipiravir for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. interferon
vs. Immunosuppressants drugs
vs. anti-interleukin-6
vs. tocilizumab
vs. antiviral and associated therapy
vs. chloroquine and derivatives
vs. chloroquine
vs. hydroxychloroquine
vs. favipiravir
vs. lopinavir/ritonavir
vs. umifenovir (arbidol)
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

jRCTs041190120, 2020 jRCTs041190120

favipiravir vs. favipiravir

COVID 19 all comers

NCT04376814-Group A, 2020 NCT04376814

favipiravir vs. hydroxychloroquine

COVID 19 all comers

NCT04411433, 0 NCT04411433

favipiravir vs. hydroxychloroquine

COVID 19 all comers

Calik, 2020

favipiravir vs. hydroxychloroquine

COVID 19 all comers

IRCT20150808023559N20, 0 IRCT20150808023559N2

favipiravir vs. hydroxychloroquine

COVID 19 all comers

Cai -FAVIPIRAVIR, 2020 ChiCTR2000029600

favipiravir vs. interferon

COVID 19 all comers

First Affiliated Hospital, Zhejiang University's Medical School, 0 ChiCTR2000029548

favipiravir vs. lopinavir/ritonavir

COVID 19 all comers

IRCT20150808023559N20, 0 IRCT20150808023559N2

favipiravir vs. lopinavir/ritonavir

COVID 19 all comers

Cai -FAVIPIRAVIR, 2020 ChiCTR2000029600

favipiravir vs. lopinavir/ritonavir

COVID 19 all comers

NCT04376814-Group A, 2020 NCT04376814

favipiravir vs. lopinavir/ritonavir

COVID 19 all comers

NCT04558463, 0 NCT04558463

favipiravir vs. oseltamivir

COVID 19 all comers

McMahon, 2020 NCT04445467

favipiravir vs. placebo

COVID 19 all comers

NCT04499677, 0 NCT04499677

favipiravir vs. placebo

COVID 19 all comers

NCT04319900 (favipirarir), 0 NCT04319900

favipiravir vs. placebo

COVID 19 all comers

NCT04333589, 0 NCT04333589

favipiravir vs. standard of care

COVID 19 all comers

Lou (FAVIPIRAVIR), 2020 ChiCTR2000029544

favipiravir vs. standard of care

COVID 19 all comers

NCT04402203, 0 NCT04402203

favipiravir vs. standard of care

COVID 19 all comers

THDMS-COVID19 -favipiravir, 0 NCT04303299

favipiravir vs. standard of care

COVID 19 all comers

NCT04358549, 0 NCT04358549

favipiravir vs. standard of care

COVID 19 all comers

NCT04373733, 2020 NCT04373733

favipiravir vs. standard of care

COVID 19 all comers

jRCTs041190120, 0 jRCTs041190120

favipiravir vs. standard of care

COVID 19 all comers

NCT04310228 -FAVI, 0 NCT04310228

favipiravir vs. tocilizumab

COVID 19 all comers

NCT04310228-FAVI (Zhao), 2020 ChiCTR2000030894

favipiravir vs. tocilizumab

COVID 19 all comers

Chang Chen et al., 2020 ChiCTR2000030254

favipiravir vs. umifenovir (arbidol)

COVID 19 all comers

ChiCTR2000030254, 0 ChiCTR2000030254

favipiravir vs. umifenovir (arbidol)

COVID 19 all comers

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open